Guggenheim Capital LLC Crispr Therapeutics Ag Transaction History
Guggenheim Capital LLC
- $14 Billion
- Q3 2024
A detailed history of Guggenheim Capital LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Guggenheim Capital LLC holds 87,871 shares of CRSP stock, worth $3.8 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
87,871
Previous 53,353
64.7%
Holding current value
$3.8 Million
Previous $2.88 Million
43.32%
% of portfolio
0.03%
Previous 0.02%
Shares
16 transactions
Others Institutions Holding CRSP
# of Institutions
491Shares Held
59.8MCall Options Held
1.1MPut Options Held
1.72M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$389 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA7.93MShares$343 Million0.07% of portfolio
-
State Street Corp Boston, MA2.99MShares$130 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$120 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.75MShares$119 Million1.21% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.38B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....